

June 14, 2022

Ref. No.: HDFC Life/CA/2022-23/26

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No C/1, Block G,
Bandra-Kurla Complex,
Bandra (East),
Mumbai- 400 051

NSE Symbol: HDFCLIFE

Listing Department
BSE Limited
Sir PJ Towers,
Dalal Street,
Fort,
Mumbai – 400 001

BSE Security Code: 540777

Dear Sir/ Madam,

Sub: Committee Meeting Intimation – Approval of terms of issuance for subordinated non-convertible debentures

We refer to the intimation of outcome of the Board Meeting held on April 26, 2022. In this regard, we wish to draw your attention to the in-principle approval accorded by the Board of Directors of the Company (“**Board**”) for raising of funds through issuance of non-convertible debentures in the nature of subordinated debt instrument up to ₹ 350 crore (Rupees three hundred and fifty crore only) in one or more tranches, on private placement basis, subject to receipt of regulatory approvals and terms and conditions as may be finalised by the Capital Raising Committee of the Board (“**CRC**”).

We wish to inform you that pursuant to the in-principle approval of the Board as mentioned aforesaid, a meeting of the CRC is scheduled to be held on Friday, June 17, 2022, *inter-alia*, to transact the following business:

- To approve the commercial terms of the proposed issuance of up to 3,500 unsecured, rated, listed, subordinated, redeemable, non-convertible, fully paid-up debentures each having a face value of ₹ 10,00,000/- (Rupees ten lakh only) of the aggregate nominal value of up to ₹ 350 crore (Rupees three hundred and fifty crore only) for cash, at par, in dematerialised form on private placement basis, and in terms of the Insurance Regulatory Development Authority of India (Other Forms of Capital) Regulations, 2015.

This is for your information and appropriate dissemination.

Thanking you,

For HDFC Life Insurance Company Limited

Narendra Gangan
General Counsel, Chief Compliance Officer &
Company Secretary